Payment overview · 2025
General Payments
$243.77
13 reported records · 8 companies
Healthcare provider profile · identity verified
Robert Blaine Kolbe, MD
Allopathic & Osteopathic Physicians|Family Medicine · BREMEN, IN · NPI 1639118839
Verified facts
What the public records show
CMS Open Payments records show Robert Blaine Kolbe, MD received $243.77 in general payments during 2025 across 13 reported records.
AstraZeneca Pharmaceuticals LP accounted for 28.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $68.54 | 28.1% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $46.07 | 18.9% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.62 | 13.8% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$28.86 | 11.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.87 | 7.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.15 | 7.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $15.68 | 6.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.98 | 6.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $243.77 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $34.32 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $33.62 | 2 | 2025 |
Source payment records
|
|||||
| CONCERTOTM Normalized: concertotm |
Device | Medtronic, Inc. | $28.86 | 1 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $27.45 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.87 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.62 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.79 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.15 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.43 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 56 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
56 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 413 | 111 |
| Losartan Potassium | Losartan Potassium | 291 | 86 |
| Amlodipine Besylate | Amlodipine Besylate | 263 | 74 |
| Levothyroxine Sodium | Levothyroxine Sodium | 262 | 77 |
| Lisinopril | Lisinopril | 190 | 58 |
| Potassium Chloride | Potassium Chloride | 152 | 54 |
| Metformin Hcl | Metformin Hcl | 148 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 148 | 39 |
| Furosemide | Furosemide | 134 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 108 | 36 |
| Omeprazole | Omeprazole | 102 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 95 | 14 |
| Allopurinol | Allopurinol | 90 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 90 | 12 |
| Famotidine | Famotidine | 83 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 82 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 80 | 26 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 79 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 79 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 77 | 23 |
| Eliquis | Apixaban | 76 | 19 |
| Gabapentin | Gabapentin | 67 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 67 | 21 |
| Sertraline Hcl | Sertraline Hcl | 63 | 21 |
| Prednisone | Prednisone | 62 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 58 | 21 |
| Topiramate | Topiramate | 58 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 56 | 12 |
| Baclofen | Baclofen | 55 | suppressed |
| Atenolol | Atenolol | 54 | 14 |
| Meloxicam | Meloxicam | 52 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 47 | 23 |
| Lorazepam | Lorazepam | 43 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | 12 |
| Alprazolam | Alprazolam | 38 | 13 |
| Cephalexin | Cephalexin | 38 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 38 | 15 |
| Cefdinir | Cefdinir | 37 | 28 |
| Finasteride | Finasteride | 36 | 12 |
| Mirtazapine | Mirtazapine | 35 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 26 |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Mounjaro | Tirzepatide | 33 | suppressed |
| Carvedilol | Carvedilol | 31 | 11 |
| Montelukast Sodium | Montelukast Sodium | 29 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Jardiance | Empagliflozin | 28 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 27 | 11 |
| Simvastatin | Simvastatin | 27 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 24 | 12 |
| Celecoxib | Celecoxib | 22 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 17 |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 17 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 17 | suppressed |
| Sulindac | Sulindac | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Indapamide | Indapamide | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Ozempic | Semaglutide | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 11 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Fluocinonide | Fluocinonide | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $243.77 · 13 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CONCERTOTM, Cologuard Collection Kit, DALVANCE, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, Kerendia, TRELEGY ELLIPTA, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error